SAM
CBAY

Silphium Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Silphium Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,012
Closed -$133K – 104
2018
Q3 		$133K Hold
12,012
– – 0.04% 124
2018
Q2 		$161K Sell
12,012
-20,000
-62% -$250K 0.05% 102
2018
Q1 		$416K Buy
+32,012
New +$398K 0.23% 47

Other funds holding CBAY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Silphium Asset Management's CBAY Position: Q4 2018 in Review

Silphium Asset Management sold out of Cymabay Therapeutics (CBAY) in Q4 2018, closing a stake of 12,012 shares — an estimated $133K sold.

Silphium Asset Management first reported a position in CBAY in Q1 2018 and held it in 3 quarters. The position peaked at $416K in Q1 2018. 131 funds tracked by Wall St. Rank hold CBAY as of Q4 2018.

  • Silphium Asset Management reported no remaining Cymabay Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Silphium Asset Management sold 12,012 Cymabay Therapeutics shares in Q4 2018, an estimated $133K.
  • Silphium Asset Management first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 3 quarters.
  • Silphium Asset Management's Cymabay Therapeutics position peaked at $416K in Q1 2018.
  • 131 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2018.

Based on Silphium Asset Management's 13F filing for Q4 2018, filed 30 Jan 2025.